Eli Lilly and Company LLY will report its third-quarter 2024 earnings on Oct. 30, before market open. The Zacks Consensus Estimate for sales and earnings is pegged at $12.03 billion and $1.53 per ...

A month has gone by since the last earnings report for Eli Lilly (LLY). Shares have lost about 5% in that time frame, underperforming the S&P 500. Will the recent negative trend continue leading up to ...

Eli Lilly secured federal approval for Emgality, the first migraine treatment approved in the U.S. for decreasing the frequency of episodic cluster headache attacks, the FDA announced June 4. 1.

The healthcare bellwether’s performance has been mixed, with the company exceeding earnings expectations in three of the trailing four quarters. It delivered a four-quarter earnings surprise of 8.47%, ...